Clozapine/haloperidol/haloperidol decanoate

2021 ◽  
Vol 1853 (1) ◽  
pp. 144-144
Keyword(s):  
Haloperidol Decanoate

scholarly journals Neuroleptic Malignant Syndrome Caused by Haloperidol Decanoate.

2002 ◽  
Vol 13 (5) ◽  
pp. 269-273
Author(s):  
Atsushi Yamaguchi ◽  
Takashi Mato ◽  
Koichi Inokuchi ◽  
Naoko Kamimura ◽  
Hajime Shiga ◽  
...  
Keyword(s):  
Neuroleptic Malignant Syndrome ◽  
Haloperidol Decanoate

Haloperidol decanoate

2010 ◽  
Vol &NA; (1330) ◽  
pp. 22
Author(s):  
&NA;
Keyword(s):  
Haloperidol Decanoate

Chemometric Assisted Development and Validation of a Stability-indicating LC Method for Determination of Related Substances in Haloperidol Decanoate Injection

2021 ◽  
Vol 55 (3) ◽  
pp. 904-915
Author(s):  
Sudheer Kolla Babu ◽  
Madhusudhan Vallabhaneni Rao ◽  
Srinivasa Puttagunta Babu ◽  
Murthy Veera Venkata Satyanarayana Chakka
Keyword(s):  
Haloperidol Decanoate ◽  
Stability Indicating ◽  
Related Substances ◽  
Development And Validation

halopéridol décanoate

2009 ◽  
pp. 494
Author(s):  
Guillaume Chevrel ◽  
Virginie Dessus
Keyword(s):  
Haloperidol Decanoate

Loading Strategies in Acute Mania

CNS Spectrums ◽  
2001 ◽  
Vol 6 (11) ◽  
pp. 919-922, 930 ◽  
Author(s):  
Brendan T. Carroll ◽  
Arthur Thalassinos ◽  
Jay D. Fawver
Keyword(s):  
Valproic Acid ◽  
Length Of Stay ◽  
Adverse Effects ◽  
Patient Selection ◽  
High Light ◽  
Acute Mania ◽  
Divalproex Sodium ◽  
Haloperidol Decanoate ◽  
Potential Benefits ◽  
Selection For

AbstractTreatment of acute mania has been greatly influenced by loading strategies. Loading has potential benefits, including rapid symptom reduction in mania and a shortened length of stay. Disadvantages include an increased likelihood of adverse effects of the medications. Loading strategies for lithium, valproic acid (divalproex sodium), carbamazepine, oxcarbazepine, olanzapine, and haloperidol decanoate in the treatment of acute mania are discussed. Recent studies high-light this treatment option for selected patients. It is the unique properties of the medications that influence their use in loading. Issues in patient selection for loading strategies with each medication are also considered.

scholarly journals Use of long acting antipsychotics and relationship to newly diagnosed bipolar disorder: a pragmatic longitudinal study based on a Canadian health registry

2020 ◽  
Vol 10 ◽  
pp. 204512532095711
Author(s):  
Emmanuel Stip ◽  
Syed Javaid ◽  
Jonathan Bayard-Diotte ◽  
Karim Abdel Aziz ◽  
Danilo Arnone
Keyword(s):  
Bipolar Disorder ◽  
Newly Diagnosed ◽  
Limited Data ◽  
Major Depressive ◽  
Haloperidol Decanoate ◽  
Number Of Patients ◽  
Prescribing Trends ◽  
Canadian Health ◽  
Long Acting ◽  
Health Registry

Background: There is limited data from large naturalistic studies to inform prescribing of long-acting injectable medication (LAIs). Guidance is particularly rare in the case of primary mood disorders. Methods: This study describes prescribing trends of LAIs in 3879 patients in Quebec, Canada, over a period of 4 years. Health register data from the Quebec provincial health plan were reviewed. Results: In this specific registry, 32% of patients who received LAIs drugs for schizophrenia had a confirmed diagnosis of bipolar disorder and 17% had a diagnosis of major depressive disorder. Non-schizophrenia syndromes were preferentially prescribed risperidone long-acting antipsychotic, whereas patients with schizophrenia were prescribed an excess of haloperidol decanoate. Patients with non-schizophrenia disorders prescribed long-acting antipsychotics were more frequently treated in primary care compared with patients with schizophrenia. Conclusion: Data from a large number of patients treated naturalistically in Quebec with long-acting antipsychotics suggests that these compounds, prescribed to treat symptoms of schizophrenia and schizoaffective disorders, were maintained when mood symptoms emerged, even in cases when the diagnosis changed to bipolar disorder. This pragmatic study supports the need to explore this intervention as potential treatment for affective disorders.

Pharmacokinetics and Therapeutic Efficacy of Haloperidol Decanoate after Loading Dose Administration

1986 ◽  
Vol 148 (5) ◽  
pp. 560-566 ◽  
Author(s):  
H. De Cuyper ◽  
J. Bollen ◽  
H. M. van Praag ◽  
D. Verstraeten
Keyword(s):  
Plasma Level ◽  
Open Study ◽  
Oral Treatment ◽  
Oral Dosage ◽  
Loading Dose ◽  
Haloperidol Decanoate ◽  
Dose Administration ◽  
The Third ◽  
Stable Plasma ◽  
Depot Injections

For this open study, we selected 21 chronic psychotic female in-patients (16 of them schizophrenics) who were being maintained on oral neuroleptics. After a wash-out period, they were treated by intramuscular depot injections of haloperidol decanoate, once a month for four months. The dose was calculated from the previous oral dosage, and the amount of the first injection was double that of the three following injections. Relatively stable plasma levels of haloperidol were achieved with the first injection, and corresponded to those observed with oral medication. A very significant correlation was found between plasma level and the dose administered, but not between plasma level and therapeutic effect. The clinical condition of about two-thirds of the patients remained unchanged or improved, compared with the period of oral treatment. During the first two months of treatment, there was more rigidity and tremor, but from the third month, the extrapyramidal symptoms were less pronounced than during the period of oral neuroleptics.

12-Month Study of Haloperidol Decanoate in Chronic Schizophrenie Patients

1982 ◽  
Vol 17 (4) ◽  
pp. 247-254 ◽  
Author(s):  
Y.G. Gelders ◽  
A.J.M. Reyntjens ◽  
C.W. Ash ◽  
A.J.L. Aerts
Keyword(s):  
Haloperidol Decanoate
Sign in / Sign up

Export Citation Format

Share Document